Targeted Vault Nanoparticles Engineered with an Endosomolytic Peptide Deliver Biomolecules to the Cytoplasm
Source abstract
Abstract
Vault nanoparticles were engineered to enhance their escape from the endosomal compartment by fusing a membrane lytic peptide derived from adenovirus protein VI (pVI) to the N-terminus of the major vault protein to form pVI-vaults. We demonstrate that these pVI-vaults disrupt the endosomal membrane using three different experimental protocols including (1) enhancement of DNA transfection, (2) co-delivery of a cytosolic ribotoxin, and (3) direct visualization by fluorescence. Furthermore, direct targeting of vaults to specific cell surface epidermal growth factor receptors led to enhanced cellular uptake and efficient delivery of vaults to the cytoplasm. This process was monitored with fluorescent vaults, and morphological changes in the endosomal compartment were observed. By combining targeting and endosomal escape into a single recombinant vault, high levels of transfection efficiency were achieved using low numbers of vault particles. These results demonstrate that engineered vaults are effective, efficient, and nontoxic nanoparticles for targeted delivery of biomaterials to the cell cytoplasm.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Virus-based gene therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biological Chemistry, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, United States
Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California 92037, United States
California NanoSystems Institute at UCLA, Los Angeles, California 90095, United States
References (51)
Show source-provided references
1. During M. J. · Adv. Drug Delivery Rev. · 1997 · 27 · 8310.1016/S0169-409X(97)00024-0 ↗
2. Felgner P. L. · Proc. Natl. Acad. Sci. U.S.A. · 1987 · 84 · 741310.1073/pnas.84.21.7413 ↗
3. Felgner P. L. · Hum. Gene Ther. · 1996 · 7 · 179110.1089/hum.1996.7.15-1791 ↗
4. Pedroso de Lima M. C. · Adv. Drug Delivery Rev. · 2001 · 47 · 27710.1016/S0169-409X(01)00110-7 ↗
5. Boussif O. · Proc. Natl. Acad. Sci. U.S.A. · 1995 · 92 · 729710.1073/pnas.92.16.7297 ↗
6. Ogris M. · Drug Discovery Today · 2002 · 7 · 47910.1016/S1359-6446(02)02243-2 ↗
7. Harada-Shiba M. · Gene Ther. · 2002 · 9 · 40710.1038/sj.gt.3301665 ↗
8. Cappello J. · Biotechnol. Prog. · 1990 · 6 · 19810.1021/bp00003a006 ↗
9. Mahat R. I. · Curr. Opin. Mol. Ther. · 1999 · 1 · 226
10. Chowdhury E. H. · Curr. Gene Ther. · 2005 · 5 · 66910.2174/156652305774964613 ↗
11. Kakizawa Y. · Adv. Mater. · 2004 · 16 · 69910.1002/adma.200305782 ↗
12. Lundstrom K. · Trends Biotechnol. · 2003 · 21 · 11710.1016/S0167-7799(02)00042-2 ↗
13. Fischer D. · Pharm. Res. · 1999 · 16 · 127310.1023/A:1014861900478 ↗
14. Plank C. · Hum. Gene Ther. · 1996 · 7 · 143710.1089/hum.1996.7.12-1437 ↗
15. Merdan T. · Pharm. Res. · 2002 · 19 · 14010.1023/A:1014212630566 ↗
16. Mesnil M. · Cancer Res. · 2000 · 60 · 3989
17. Suprenant K. A. · Biochemistry · 2002 · 41 · 1444710.1021/bi026747e ↗
18. Kedersha N. L. · J. Cell Biol. · 1991 · 112 · 22510.1083/jcb.112.2.225 ↗
19. Kickhoefer V. A. · J. Cell Biol. · 1999 · 146 · 91710.1083/jcb.146.5.917 ↗
20. Kickhoefer V. A. · J. Biol. Chem. · 1999 · 274 · 3271210.1074/jbc.274.46.32712 ↗
21. Kickhoefer V. A. · J. Biol. Chem. · 1993 · 268 · 786810.1016/S0021-9258(18)53038-6 ↗
22. Kickhoefer V. A. · J. Biol. Chem. · 1998 · 273 · 897110.1074/jbc.273.15.8971 ↗
23. van Zon A. · J. Biol. Chem. · 2001 · 276 · 3771510.1074/jbc.M106055200 ↗
24. Stephen A. G. · J. Biol. Chem. · 2001 · 276 · 2321710.1074/jbc.C100226200 ↗
25. Mikyas Y. · J. Mol. Biol. · 2004 · 344 · 9110.1016/j.jmb.2004.09.021 ↗
26. Anderson D. H. · PLoS Biol. · 2007 · 5 · e31810.1371/journal.pbio.0050318 ↗
27. Kickhoefer V. A. · Proc. Natl. Acad. Sci. U.S.A. · 2005 · 102 · 434810.1073/pnas.0500929102 ↗
28. Ng B. C. · Nano Lett. · 2008 · 8 · 350310.1021/nl080537r ↗
29. Yu M. · Nano Lett. · 2008 · 8 · 351010.1021/nl080536z ↗
30. Champion C. I. · PLoS One · 2009 · 4 · e540910.1371/journal.pone.0005409 ↗
31. Kickhoefer V. A. · ACS Nano · 2009 · 3 · 2710.1021/nn800638x ↗
32. Goldsmith L. E. · Biochemistry · 2007 · 46 · 286510.1021/bi0606243 ↗
33. Poderycki M. J. · Biochemistry · 2006 · 45 · 1218410.1021/bi0610552 ↗
34. Esfandiary R. · J. Pharm. Sci. · 2009 · 98 · 137610.1002/jps.21508 ↗
35. Yang J. · ACS Nano · 2010 · 4 · 722910.1021/nn102051r ↗
36. Tanaka H. · Science · 2009 · 323 · 38410.1126/science.1164975 ↗
37. Nilsson B. · Protein Eng. · 1987 · 1 · 10710.1093/protein/1.2.107 ↗
38. van Zon A. · Biochem. Biophys. Res. Commun. · 2002 · 291 · 53510.1006/bbrc.2002.6472 ↗
39. Kozlov G. · J. Mol. Biol. · 2006 · 356 · 44410.1016/j.jmb.2005.11.064 ↗
40. 10.1371/journal.pone.0018758.10.1371/journal.pone.0018758. ↗
41. 10.1002/smll.201002274.10.1002/smll.201002274. ↗
42. Wiethoff C. M. · J. Virol. · 2005 · 79 · 199210.1128/JVI.79.4.1992-2000.2005 ↗
43. Lai C. Y. · ACS Nano · 2009 · 3 · 69110.1021/nn8008504 ↗
44. Seiler M. P. · Mol. Ther. · 2007 · 15 · 38610.1038/sj.mt.6300029 ↗
45. Eisenstein M. A. · Nat. Methods · 2005 · 2 · 31810.1038/nmeth0405-318 ↗
46. Varga C. M. · Gene Ther. · 2005 · 12 · 102310.1038/sj.gt.3302495 ↗
47. Moyer C. L. · J. Virol. · 2011 · 85 · 263110.1128/JVI.02321-10 ↗
48. Shaughnessy L. M. · Cell Microbiol. · 2006 · 8 · 78110.1111/j.1462-5822.2005.00665.x ↗
49. Kingdon G. C. · Infect. Immun. · 1970 · 1 · 35610.1128/iai.1.4.356-362.1970 ↗
50. Xie H. · J. Cell Sci. · 1998 · 111 · 61510.1242/jcs.111.5.615 ↗
51. Wells A. · Int. J. Biochem. Cell Biol. · 1999 · 31 · 63710.1016/S1357-2725(99)00015-1 ↗